What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “KL-A167 4-6 cycles for combined therapy.KL-A167 maintenance.”In the company’s words, NCT05294172 on ClinicalTrials.gov
- Tested for
- Nasopharyngeal Carcinoma, Recurrent or Metastatic, Non-small Cell Lung Cancer, Small Cell Lung Cancer
- Main trialPhase 3
- “The study is to evaluate the efficacy of KL-A167 combined with cisplatin and gemcitabine vs placebo combined with cisplatin and gemcitabine in the treatment of recurrent or metastatic nasopharyngeal carcinoma, as measured by progression-free survival (PFS) per the Response Evaluation Criteria in Solid Tumors RECIST Version 1.1”In the company’s words, NCT05294172 on ClinicalTrials.gov
Other drugs for Nasopharyngeal Carcinoma
- Izalontamab brengitecanSichuan Baili (Biokin, SystImmune) · Bristol Myers Squibb · Phase 3
- Tambotatug pelitecanMediLink Therapeutics (Suzhou) Co., Ltd. · Phase 3
- MRG003Lepu Biopharma Co., Ltd. · Phase 3
- PucotenlimabLepu Biopharma Co., Ltd. · Phase 3
- EnlonstobartCSPC · Phase 3
- SYS6010CSPC · Phase 3
Coming up2
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2027 | KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma | |
| Phase 2Recruiting | Aug 2026 | SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | |
| Phase 2Recruiting | 31 Dec 2028 | SKB500 Combinations in Patients With Small Cell Lung Cancer | |
| Phase 2Completed | 22 Aug 2020 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | |
| Phase 2Completed | 13 Jul 2021 | KL-A167 Injection in Recurrent or Metastatic Nasopharyngeal Carcinoma | |
| Phase 2Completed | 31 Jul 2026 | SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026